---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-23-023999"
form_type: "8-K"
ticker: "RVPH"
cik: "0001742927"
company_name: "REVIVA PHARMACEUTICALS HOLDINGS, INC."
filed_at: "2023-08-17T23:59:59+00:00"
generated_at: "2026-06-11T07:46:56.597855+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Reviva completes enrollment in Phase 3 RECOVER study for brilaroxazine in schizophrenia; topline data expected Oct 2023

## Summary
- Enrollment of 402 patients across US (~60%), Europe (~10%), and Asia (~30%) in pivotal Phase 3 RECOVER trial.
- Topline efficacy and safety data for RECOVER expected in October 2023.
- Over 50% of patients enrolled in 1-year open-label extension study; completion expected in Q3 2024.
- Primary endpoint: change in PANSS total score from baseline to Day 28 vs placebo.

## SEC filing metadata
- accession: 0001437749-23-023999
- form_type: 8-K
- ticker: RVPH
- cik: 0001742927
- company_name: REVIVA PHARMACEUTICALS HOLDINGS, INC.
- filed_at: 2023-08-17T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1742927/000143774923023999/0001437749-23-023999-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1742927/000143774923023999/rvph20230816_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-23-023999
- JSON: https://secwatch.observer/filing/0001437749-23-023999.json
- Plain text: https://secwatch.observer/filing/0001437749-23-023999.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.